Back to Search
DR. NITIN S DAMLE MD
MD
Internal Medicine Physician
NPI: 1457399388IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
MD07066(RI)
Education
WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE
Class of 1985
Research & Publications (20)
Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.
PMID 15335312·Expert Opin Biol Ther·2004
6-review
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.
PMID 12901947·Curr Opin Pharmacol·2003
6-review
The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.
PMID 18097562·Int J Oncol·2008
7-preclinical
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.
PMID 17668210·Cancer Chemother Pharmacol·2008
7-preclinical
Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis.
PMID 18171218·Clin Infect Dis·2008
8-other
Prospective study of serologic tests for lyme disease.
PMID 18532885·Clin Infect Dis·2008
4-observational
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
PMID 17657218·Leukemia·2007
7-preclinical
CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
PMID 17160682·Cancer Immunol Immunother·2007
7-preclinical
Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease.
PMID 17035489·J Clin Microbiol·2006
8-other
Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
PMID 16465373·Int J Oncol·2006
4-observational
Biopharmaceutical drug discovery using novel protein scaffolds.
PMID 17055245·Curr Opin Biotechnol·2006
6-review
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
PMID 16397048·Clin Cancer Res·2006
7-preclinical
B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.
PMID 15947095·Blood·2005
7-preclinical
Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
PMID 15693135·Cancer Immunol Immunother·2005
7-preclinical
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
PMID 15623646·Clin Cancer Res·2004
7-preclinical
Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
PMID 15240546·Clin Cancer Res·2004
7-preclinical
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
PMID 14615373·Blood·2004
7-preclinical
Inflammatory cytokine production predominates in early Lyme disease in patients with erythema migrans.
PMID 14500528·Infect Immun·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 481 KINGSTOWN RD
WAKEFIELD, RI 02879 - Phone
- (401) 789-0283
Quick Facts
- NPI
- 1457399388
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile